Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...

A study reveals advances in the understanding and treatment of liver fibrosis, a serious complication in the context of metabolic fatty liver disease, also known as MASLD (metabolic ...

Cytotheryx, a growing Rochester biotech firm working on treatments for liver disease, recently received $60 million in financing to advance its research and development. CEO Dr. John Swart announced ...

An international team of researchers bioengineering human liver tissues uncovered previously unknown networks of genetic-molecular crosstalk that control the organ's developmental processes – greatly ...

The liver is accountable for metabolizing most medications and is therefore one of the primary tissues affected by adverse drug reactions. Most classes of medicine can cause drug-induced liver injury ...

Cardiovascular disease is a leading cause of mortality worldwide, affecting both men and women significantly. Liver diseases, including cirrhosis, ...

VivoSim Labs' NAMkind™ platform shows 87.5% predictive accuracy for liver toxicity, enhancing drug safety and reducing development costs. VivoSim Labs, Inc. announced the successful performance of its ...